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Summary
 
Objective 
 
To evaluate the efﬁcacy, safety and tolerability of octre-
otide LAR
 
®
 
 (long-acting repeatable octreotide) in the primary therapy
of acromegaly.
 
Design and patients 
 
Ninety-eight previously untreated acrome-
galics were recruited into this prospective multicentre study. A total
of 68 patients successfully completed 48 weeks of the study period,
received 12 doses of octreotide LAR 10–30 mg every 4 weeks, and
constituted the population used for this analysis.
 
Measurements and results 
 
A clinically relevant reduction (i.e.
to 
 
≤
 
 5 
 
µ
 
g/l) in mean GH (mGH) was recorded in 72% of patients
after 24  weeks of treatment, and 42% reached a ‘safe’ GH value
(
 
≤
 
 2·5 
 
µ
 
g/l). At week 48, 16 more patients were considered partial
GH responders (GH 
 
>
 
 2·5 
 
µ
 
g/l and 
 
≤
 
 5 
 
µ
 
g/l) and 44% had reached
a GH level 
 
≤
 
 2·5 
 
µ
 
g/l. IGF-1 levels normalized in 38% and 34% of
patients after 24 and 48 weeks of treatment, respectively. At study
completion, 10 patients (14·7%) who had not normalized their IGF-
1 levels had achieved at least a 50% decrement in this marker. In eight
microadenoma patients, tumour volume decreased from a mean
baseline level of 298 
 
±
 
 145 mm
 
3
 
 to 139 
 
±
 
 94 mm
 
3
 
 after 24 weeks and
to 99 
 
±
 
 70 mm
 
3
 
 after 48 weeks of therapy. In 60 patients with macro-
adenoma, the corresponding values were 3885 
 
±
 
 5077 mm
 
3
 
  at
baseline and 2723 
 
±
 
 3435 and 2406 
 
±
 
 3207 mm
 
3
 
 after 24 and 48 weeks,
respectively. At weeks 24 and 48, a signiﬁcant (
 
>
 
 20%) tumour
volume reduction was reported in 63% and 75% of patients, respec-
tively. A reduction in the severity of symptoms of acromegaly was
observed early in treatment and was maintained throughout the
study period.
 
Conclusion 
 
Octreotide LAR represents a viable alternative to sur-
gery for primary treatment of acromegaly leading to a progressive
regression of tumour volume, a sustained control of biochemical
abnormalities and an adequate relief of symptoms of the disease.
(Received 20 January 2006; returned for revision 23 March 2006; 
 
ﬁnally revised 28 December 2006; accepted 28 December 2006)
 
Introduction
 
Acromegaly results from an excess secretion of GH from a pituitary
adenoma leading to an increase in IGF-1 concentrations.
 
1,2
 
  The
symptoms are due to the effects of both GH and IGF-1 on cartilage,
soft tissues and organs, such as the heart, and the compression of
the surrounding tissues by the tumour itself, which results in head-
ache, visual ﬁeld defects and hypopituitarism.
 
1,2
 
 Patients with active
acromegaly have an elevated morbidity and mortality that correlate
with the elevated plasma levels of GH and IGF-1.
 
3,4
 
The principal objectives in the treatment of acromegaly are: (1)
to halt or reverse tumour growth, thereby controlling symptoms of
compression, (2) to improve symptoms and comorbidities resulting
from the excessive plasma concentrations of GH and IGF-1 and (3)
to eliminate the increased mortality rate associated with the disease
by effectively reducing GH and by normalizing IGF-1 concentrations.
 
5–7
 
Although surgical remission rates achieved in patients with micro-
adenomas are high, provided an experienced pituitary neurosurgeon
performs the procedure (depending on the deﬁnition of cure,
80–90%),
 
8,9
 
 over 70% of acromegalic patients harbour macro-
adenomas and have surgical cure rates of less than 50%, even in the most
experienced hands.
 
10,11
 
 However, the frequent presence of tumour
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in inaccessible sites such as the cavernous sinuses can make surgical
attempts futile. Therefore, for a signiﬁcant proportion of patients,
surgery does not represent a satisfactory form of therapy.
Primary pharmacological therapy of patients with acromegaly
with depot somatostatin analogues can be effective, both in terms
of GH and IGF-1 control and in reducing tumour volume.
 
12–16
 
 In
general, these series report biochemical success rates (achievement
of a GH value 
 
<
 
 2·5 
 
µ
 
g/l and a normal IGF-1 level) that range
between 40% and 70%. The present multicentre, international study
was undertaken to evaluate the efﬁcacy and safety of octreotide LAR
 
®
 
(long-acting repeatable octreotide) in a rigorously controlled,
prospective setting, with particular emphasis on accurate tumour
volume measurements and their correlation with clinical and
biochemical outcome.
 
Patients and methods
 
This prospective, open-label international multicentre study was
carried out at selected neuroendocrinological clinics to investigate
the feasibility of using octreotide LAR administered by intra-
muscular (i.m.) injection at intervals of 4 weeks, as the primary medical
therapy of previously untreated acromegalic patients. A total of 31
centres in 15 countries participated, recruiting patients into the
study between December 2002 and August 2003.
 
Patients
 
Male or female patients aged 18–80 years with previously untreated
acromegaly who provided their written informed consent were eli-
gible to participate in the study. Biochemical diagnosis of acromegaly
required both a lack of GH suppression to 
 
<
 
 1 
 
µ
 
g/l after a 75-g oral
glucose load and an elevated IGF-1 to above the 97th percentile of
the normal range adjusted for age and gender.
Excluded from the investigation were patients who had received
any prior therapy for acromegaly, those with signiﬁcant deteriora-
tion of visual ﬁelds or other neurological signs related to the tumour
mass or signiﬁcant medical conditions that may have interfered with
the study. Also excluded were patients in whom magnetic resonance
imaging (MRI) revealed no evidence of a pituitary adenoma, those
being treated with any drug for the inhibition of prolactin secretion
or patients with a history of symptomatic cholelithiasis. The experi-
mental protocol was approved by the independent ethical review
committees of each centre participating in the study.
 
Study design
 
At the screening visit blood was collected for GH measurement at
0 (after 1 h rest), 30, 60, 90 and 120 min and, subsequently, a sub-
cutaneous (s.c.) 100 
 
µ
 
g octreotide test dose was administered to ensure
that the drug was tolerated and additional blood samples were
collected 30, 60, 90 and 120 min later. Selection of patients was not
based on the responses to the s.c. octreotide test. Patients who ful-
ﬁlled all the criteria for study participation then commenced therapy
with octreotide LAR 20 mg i.m. At week 12, after three doses of octre-
otide LAR had been administered, mean GH (mGH) and IGF-1 were
measured prior to the fourth injection. At week 16, dose titration was
permitted and in patients in whom mGH levels were 
 
<
 
 1 
 
µ
 
g/l and
IGF-1 was within the adjusted normal range the dose was decreased
to 10 mg, those in whom the mGH was 
 
≤
 
 2·5 
 
µ
 
g/l and the IGF-1 was
within the adjusted normal range continued to receive 20 mg and in
those in whom GH was 
 
>
 
 2·5 
 
µ
 
g/l or the IGF-1 above the adjusted normal
range the dose was increased to 30 mg. If necessary, further dose
adjustment was permitted after 24 weeks of therapy (at the week 28 visit).
 
Assessment of biochemical response
 
Serum GH and IGF-1 levels were measured at a central laboratory
(Nichols Institute Diagnostics, San Clemente, CA, USA) by immuno-
radiometric assay (IRMA). For GH, the lower limit of detection
was 0·5 
 
µ
 
g/l and the within-run coefﬁcients of variation (CVs) ranged
from 4·2% to 4·6% and between-run CVs ranged between 5·0% and
5·4%. For IGF-1 measurements, serum samples were pretreated with
acid–ethanol to allow for binding protein separation prior to the
assay, which had a detection limit of 30 
 
µ
 
g/l and intra- and interassay
CVs of 6·2% and 6·1%, respectively.
Biochemical outcome categories were deﬁned as follows:
•‘ T otal success’ was achieved when the mGH was 
 
≤
 
 2·5 
 
µ
 
g/l and age-
adjusted IGF-1 was normal.
•‘ Partial success’ was deﬁned as: (1) an mGH 
 
>
 
 2·5 
 
µ
 
g/l and 
 
≤
 
 5·0 
 
µ
 
g/l
and a decrease in IGF-I of 
 
≥
 
 50% compared to baseline, or IGF-1
within the age-adjusted laboratory normal range, or (2) an mGH
 
≤
 
 2·5 
 
µ
 
g/l and a decrease in IGF-I of 
 
≥
 
 50% compared to the baseline
level, but IGF-I levels still above the normal range.
•‘ Treatment failure’ was deﬁned as any other response.
 
Symptoms of acromegaly
 
Patients were asked to score each of their symptoms of acromegaly
(0 
 
=
 
 absent, 1 
 
=
 
 mild, 2 
 
=
 
 moderate, 3 
 
=
 
 severe but not incapacitat-
ing or 4 
 
=
 
 severe and incapacitating) at baseline and at 16, 24 and
48 weeks of therapy. The symptoms scored were headache, fatigue,
perspiration, paresthesia, osteoarthralgia and carpal tunnel syndrome.
 
MRI studies
 
MR images were acquired at each participating site, based on the
optimum imaging protocol used in each centre, but included as
a minimum, T1-weighted sagittal and coronal sequences before
and after administration of gadolinium (in a standard diagnostic
imaging dose). The minimum scanner ﬁeld strength was 1·0 Tesla.
All image data were sent electronically (when possible) or printed onto
ﬁlm to a central image reading laboratory for blinded analysis.
The pituitary tumour measurements from the MRI scans at base-
line, week 24 and week 48 were made in a central laboratory by three
neuroradiologists blinded to all clinical and endocrine data. Pituitary
lesion images received electronically from participating centres in
digital (DICOM) format were loaded directly into the image analysis
and handling software (Digital Jacket, Version 3·6; DesAcc Inc.,
Chicago, IL, USA). Images received as ﬁlm were redigitized with a
ﬁlm scanner (Multirad 450, Howtek, OH, USA) and converted to
DICOM format using Digital Jacket. The coronal images were used
for tumour volume measurements. Images were magniﬁed by a factor 
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of 2; tumour circumferences were outlined using the polygonal
outline tool on each slice on which the tumour was visible, the area
within the circumference on each slice was calculated by the Digital
Jacket program, and the thickness of each slice (slice thickness 
 
+
 
 any
gap spacing) was also recorded. Tumour volume was calculated as
the sum of each tumour slice area multiplied by the effective section
thickness.
 
17
 
 Maximum tumour diameter was determined from the
largest diameter in any plane. Tumours were classiﬁed as micro- or
macroadenomas based on the largest tumour diameter (
 
≤
 
 10 mm or
 
>
 
 10 mm, respectively).
Estimates of the accuracy and reproducibility between patient
visits due to, for example, variations in patient positioning, contrast
bolus timing and volume averaging artefacts cumulatively contributed
to a variation of at least 20%. Thus, a change in tumour volume was
only considered signiﬁcant if it exceeded 20%.
 
Gallbladder ultrasound evaluation
 
Ultrasound evaluations of the gallbladder and biliary tree were
performed at baseline and after 24 and 48 weeks of therapy with
the study drug. The results of these investigations were assessed and
interpreted locally.
 
Statistical analysis
 
The rate of treatment success and the corresponding 95% conﬁdence
interval was calculated using the normal approximation to the
binomial distribution, applying a continuity correction:
where 
 
P
 
 represents the observed proportion of treatment success,
 
z
 
α
 
/2
 
 is the 100(1 
 
−
 
 
 
α
 
/2) percentile of the normal distribution, 
 
n
 
 rep-
resents the number of patients and 
 
α
 
 
 
=
 
 0·05. For the calculation of
the conﬁdence intervals in the microadenoma patients, the method
of Clopper and Pearson
 
18
 
 was used, in consideration of the small
number of subjects in this group. Nonparametric Wilcoxon two-
sample tests (based upon rank sums) were applied to examine group
differences for continuous variables. To compare fractions between
categorical variables, 
 
χ
 
2
 
-tests or Fisher’s exact test (in the case of
small samples) were used. A 
 
P
 
-level of 5% or less was considered as
statistically signiﬁcant.
 
Results
 
Out of a total of 110 patients screened for acromegaly, 98 fulﬁlled
the protocol inclusion criteria and were started on octreotide LAR
after their informed consent had been obtained. Thirty patients were
excluded from the efﬁcacy analysis of this report, 15 because of major
protocol violations and 15 because of premature discontinuation. Of
the 15 patients who were prematurely discontinued from the study,
six discontinued as permitted by the protocol due to uncontrolled
acromegaly (GH 
 
>
 
 2·5 
 
µ
 
g/l and/or IGF-1 above the upper limit of
normal (ULN) for age), one withdrew consent and eight patients
withdrew because of adverse events (AEs). Of the latter, two cases
(one pregnancy with spontaneous abortion and one case of pancreatic
carcinoma) were considered to be unrelated to therapy whereas the
remaining six (abdominal disturbances with or without cholelithiasis)
were suspected of being drug induced. Thus, 68 patients (eight with
microadenomas and 60 with macroadenomas) completed the full
course of the investigation, receiving 12 injections of the study drug,
and constitute the per protocol population that is the subject of this
report. Their baseline clinical, biochemical and tumour volume by
MRI characteristics are presented in Table 1. Age, gender proportion,
disease duration, tumour size and biochemical severity were no
different between the 30 subjects who had to abandon the study
and the 68 who completed it. Diabetes mellitus was present in
18% of the patients at study entry. Thirty-four patients (35%, all
Total  
N = 68
Microadenomas 
N = 8
Macroadenomas 
N = 60 P*
Age (years)
Mean ± SD 49·7 ± 13·2 60 ± 9·3 48·3 ± 13·1
Median 50 57·5 47·5 0·02
Range 24–77 49–77 24–71
Male/female 28/40 4/4 24/36 0·7
mGH (µg/l)
Mean ± SD 33·6 ± 62·6 5·5 ± 2·6 37·4 ± 65·8
Median 9·5 5·3 13·1 0·008
Range 2–391 2·3–9·1 2–391
IGF-1(µg/l)
Mean ± SD 676 ± 275 570 ± 124 690 ± 287
Median 616 565 617 0·19
Range 277–1974 391–720 277–1974
Tumour volume (mm
3)
Mean ± SD 3463 ± 4905 298 ± 145 3885 ± 5077
Median 1210 308 1608 < 0·0001
Range 59–22 702 86–528 59–22 702
*Wilcoxon test for continuous variables, Fisher’s exact test for gender.
Table 1. Baseline characteristics
Pz p p n n    (  ) /       / / ±− − + [] α 2 11 1 2862 M. Mercado et al.
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Clinical Endocrinology, 66, 859–868
macroadenomas) showed mild hyperprolactinaemia at the
beginning of the study; of these, seven (7%) normalized their
prolactin while on treatment with octreotide LAR.
Drug doses
At the end of the study, among the patients with microadenomas,
one was receiving 10 mg, three were on 20 mg and four on 30 mg.
In the group with macroadenomas, four patients were treated with
10 mg, 12 with 20 mg and 44 with 30 mg.
Biochemical responses
The effects of octreotide LAR on the mean and median serum levels
of mGH and IGF-1 after 12, 24 and 48 weeks of treatment are sum-
marized in Table 2. The majority of subjects showed a beneﬁcial
effect, with substantial decreases in the serum concentrations of both
GH and IGF-1 noted as early as 12 weeks after the beginning of therapy.
In patients with microadenomas, the average reduction in mGH after
24 and 48 weeks of octreotide therapy was 71·2% and 69%, respectively.
In patients with macroadenomas, the average percentage of decrement
in mGH was 70·8% and 76% at weeks 24 and 48 of the study, respec-
tively. The average decrease in IGF-1 levels was of a smaller magnitude:
66% and 61·7% for microadenomas at weeks 24 and 48, respectively,
and 42% and 37% for macroadenomas at the same time points. The
effects of treatment on serum concentrations of GH and IGF-1 in
individual patients are illustrated in Figs 1 and 2, respectively.
A GH level of 2·5 µg/l or below was reached by 42·6% of patients
(87·5% with microadenomas, 36·7% with macroadenomas) after
24  weeks of therapy, whereas the IGF-1 level had normalized in
38·2% (75% with microadenomas and 33·3% with macroadenomas)
of treated subjects at this time point (Table 3). The proportion of
patients with a complete GH and IGF-1 response did not increase
over time (44·1% and 33·8%, respectively, at 48 weeks) (Table 3). At
the end of the study 25% of the patients had simultaneously met both
GH and IGF-1 criteria for treatment success (Table 4).
Tumour volume
Figure 3 illustrates tumour shrinkage as evidenced on serial MRI
scans and Fig. 4 depicts individual percentages in tumour volume
reduction throughout the study in micro- and macroadenomas.
The magnitude of tumour volume reduction was greater in patients
with microadenomas than in those with macroadenomas at both
24 and 48 weeks of treatment (week 24, P = 0·006; week 48, P =
0·002; Table 5). In the former group, tumour volume was reduced
from a mean baseline level of 298 ± 145 mm
3 to 139 ± 94 mm
3
after 24 weeks of treatment and to 99 ± 70 mm
3 after 48 weeks
of treatment. In patients with macroadenoma, the values were
3885 ± 5077 mm
3 at baseline, 2723 ± 3435 mm
3 after 24 weeks
and 2406 ± 3207 mm
3 after 48 weeks. At week 24, 63% of patients
(100% microadenoma and 58% macroadenoma, P = 0·02, Fisher’s
exact test) showed a substantial (≥ 20%) reduction in tumour vol-
ume whereas 75% (100% microadenoma and 72% macroadenoma,
P = 0·19, Fisher’s exact test) did so at week 48. Two patients with
microadenoma had no visible tumour on MRI by week 48.
A favourable biochemical response, be it the achievement of a
GH ≤ 2·5 µg/l and/or the normalization of IGF-1, at 12 weeks was
not predictive of a signiﬁcant reduction in tumour volume by the
end of the study. Approximately half of the initial biochemical
Table 2. Mean GH (mGH) and IGF-1 at the different follow-up visits
Visit  Difference
Baseline Week 12 Week 24 Week 48 Baseline – Week 48
Microadenoma
N 88888
mGH (µg/l) Mean 5·5 1·6 1·5 1·7 −3·8
Median 5·3 1·6 1·4 1·5 −4·1
Min, Max 2·3, 9·1 0·5, 3·1 0·5, 2·6 0·5, 4·2 −6·7, −1·1
SD 2·6 1·0 0·8 1·2 2·0
IGF-1 (µg/l) Mean 570·6 210·5 194·1 218·4 −352
Median 565·0 222·5 186·0 222·0 −344
Min, Max 391, 720 86, 354 77, 334 95, 340 −468, −203
SD 123·9 97·0 92·0 88·3 87·4
Macroadenoma
N 60 60 60 60 60
mGH (µg/l) Mean 37·4 14·3 10·9 9·0 −28·3
Median 13·9 3·0 3·2 3·3 −9·1
Min, Max 2, 391·2 0·5, 401·4 0·5, 245·2 0·5, 218·7 −245, 3·2
SD 65·8 52·5 32·6 28·3 47·6
IGF-1 (µg/l) Mean 690·3 396·2 399·2 435·6 −255
Median 617·5 345·5 383·0 381·5 −236
Min, Max 277, 1974 93, 818 92, 922 107, 1122 −1602, 258
SD 287·7 199·3 192·4 248·3 296·0Primary therapy of acromegaly with octreotide LAR 863
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responders and nonresponders showed greater than 20% tumour
shrinkage by week 48. However, biochemical responders, in general,
had signiﬁcantly smaller tumours than nonresponders (1327 vs.
5362 mm
3, P < 0·001).
Signs and symptoms of acromegaly
As shown in Table 6, there was a marked and consistent reduction
in the number and intensity of symptoms of acromegaly that was
sustained throughout the treatment period.
Tolerability
The most frequently reported AEs were gastrointestinal complaints
such as abdominal pain or discomfort, diarrhoea and nausea. Hepa-
tobiliary disorders were also reported frequently and a total of 38
patients experienced newly occurring or worsening cholelithiasis.
Baseline gallbladder ultrasound in 13 patients revealed at least one
asymptomatic hepatobiliary abnormality (gallstones, sludge or bile
duct dilation). The majority of cases of cholelithiasis were asymp-
tomatic and required no intervention. One patient underwent a
Fig. 1 Mean GH values in each individual patient 
at baseline, and after 24 and 48 weeks of treatment 
with octreotide LAR. Shaded area represents a GH 
level < 2·5 µg/l.
Fig. 2 Individual IGF-1 levels at baseline and after 
24 and 48 weeks of treatment with octreotide 
LAR. Shaded areas represent the normal, age-
adjusted range.864 M. Mercado et al.
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Table 3. GH and IGF-1 response rates after 24 and 48 weeks of treatment
Week/Outcome
Total 
N = 68% (n) [95% CI]
Microadenomas 
N = 8% (n) [95% CI]*
Macroadenomas 
N = 60% (n) [95% CI]
Week 24
Any GH response 72·1 (49) 100·0 (8)  68·3 (41)
[60·6, 83·5] [63·1, 100·0] [55·6, 81·0]
Complete GH response 42·6 (29) 87·5 (7) 36·7 (22)
(mGH ≤ 2·5 µg/l) [30·1, 55·2] [47·4, 99·7] [23·5, 49·8]
Partial response GH 29·4 (20) 12·5 (1) 31·7 (19)
(mGH > 2·5 and ≤ 5 µg/l) [17·8, 41·1] [0·0, 52·7] [19·0, 44·4]
Any IGF-1 response 55·9 (38) 100·0 (8) 50·0 (30)
[43·3, 68·5] [63·1, 100·0] [36·4, 63·6]
Complete IGF-1 response 38·2 (26) 75·0 (6) 33·3 (20)
(normal for age and sex) [25·9, 50·6] [34·9, 96·8] [20·5, 46·2]
Partial IGF-1 response 17·6 (12) 25·0 (2) 16·7 (10)
(≥ 50% reduction) [7·8, 27·5] [3·2, 65·1] [6·3, 27·0]
Week 48
Any GH response 67·6 (46) 100·0 (8) 63·3 (38)
[55·7, 79·6] [63·1, 100·0] [50·2, 76·5]
Complete GH response 44·1 (30) 75·0 (6) 40·0 (24)
(mGH ≤ 2·5 µg/l) [31·5, 56·7] [34·9, 96·8] [26·7, 53·3]
Partial GH response 23·5 (16) 25·0 (2) 23·3 (14)
(mGH > 2·5 and ≤ 5 µg/l) [12·6, 34·4] [3·2, 65·1] [11·7, 35·0]
Any IGF-1 response 48·5 (33) 75·0 (6) 45·0 (27)
[35·8, 61·2] [34·9, 96·8] [31·5, 58·5]
Complete IGF-1 response 33·8 (23) 50·0 (4) 31·7 (19)
(normal for age and sex) [21·8, 45·9] [15·7, 84·3] [19·0, 44·4]
Partial IGF-1 response 14·7 (10) 25·0 (2) 13·3 (8)
(≥ 50% reduction) [5·5, 23·9] [3·2, 65·1] [3·8, 22·8]
*Using exact calculation method because of the small number of subjects.
Table 4. Treatment success rates
Week/Outcome
Total 
N = 68% (n) 
[95% CI]
Microadenomas 
N = 8% (n) 
[95% CI]*
Macroadenomas 
N = 60% (n) 
[95% CI]
Week 24
Overall treatment success 50·0 (34) 100·0 (8) 43·3 (26)
[37·3, 62·7] [63·1, 100·0] [29·9, 56·8]
Total success 26·5 (18) 75·0 (6) 20·0 (12)
[15·2, 37·8] [34·9, 96·8] [9·0, 31·0]
Partial success 23·5 (16) 25·0 (2) 23·3 (14)
[12·6, 34·4] [3·2, 65·1] [11·7, 35·0]
Week 48
Overall treatment success 47·1 (32) 75·0 (6) 43·3 (26)
[34·4, 59·7] [34·9, 96·8] [29·9, 56·8]
Total success 25·0 (17) 37·5 (3) 23·3 (14)
[13·9, 36·1] [8·5, 75·5] [11·7, 35·0]
Partial success 22·1 (15) 37·5 (3) 20·0 (12)
[11·4, 32·7] [8·5, 75·5] [9·0, 31·0]
Total success: mean of 2-h GH proﬁle ≤ 2·5 µg/l and IGF-I levels within laboratory normal range.
Partial success: (1) mean of 2-h GH proﬁle > 2·5 and ≤ 5·0 µg/l and either a decrease in IGF-I of at least 50% in comparison to baseline levels or IGF-I levels 
within laboratory normal range, or (2) mean of 2-h GH proﬁle ≤ 2·5 µg/l and a decrease in IGF-I of at least 50% in comparison to baseline levels and IGF-I 
levels outside normal range.
*Using exact calculation method because of the small number of subjects.Primary therapy of acromegaly with octreotide LAR 865
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cholecystectomy because of acute cholecystitis but went on to com-
plete the study. Two patients were prematurely withdrawn from the
study because of clinically signiﬁcant biliary disease, one of them
with pancreatitis and cholestatic hepatitis.
Discussion
This large multicentre, international study aimed to evaluate the
safety and efﬁcacy of octreotide LAR in the primary treatment of
acromegaly. The participation of countries from Eastern and West-
ern Europe, as well as Asia and Latin America, makes this a unique
study in terms of its ethnic diversity. Ethnic factors can be important
not only in the aetiology of acromegaly but also in determining the
response to pharmacological therapy. The latter is illustrated by the
differences in the prevalence of gsp alpha mutations among Cauca-
sians,
19,20 Asian
21 and Mexican
22 patients with acromegaly and the
notion that tumours that harbour such molecular changes are less
invasive and respond better to octreotide.
20 After 48 weeks of treat-
ment, 44% of our patients had achieved a safe GH level, 34% had
normalized their IGF-1 levels and 25% achieved both criteria of
biochemical control. This biochemical response rate is somewhat
lower than the recently reported ﬁgures from two Italian groups,
23,24
whereby a safe GH and a normal IGF-1 level are achieved by almost
60% of the patients. This discrepancy in outcome may be because
these Italian studies included only Caucasian patients, whereas our
study was carried out in subjects coming from several genetic back-
grounds, including some with a low prevalence of gsp alpha muta-
tions in somatotroph adenomas.
21,22 Thus, our results derived from
a large group of otherwise unselected patients, and by using stringent
criteria for response, better represent the real success rate of soma-
tostatin analogues in previously untreated acromegaly.
In general, the study drug was well tolerated. The most frequently
reported AEs were gastrointestinal disorders including pain, dis-
comfort, distension and diarrhoea. The inclusion of repeated echo-
graphic examinations of the gallbladder and biliary tree led to the
detection of a relatively large number of cases of new or worsening
cholelithiasis. Cholelithiasis is an AE that is known to be associated
with octreotide therapy,
25 and the majority of the cases were asymp-
tomatic events that required no special interventions.
As in previously reported studies, we found that patients with
microadenomas and also those with a lower degree of hyper-
somatotrophinaemia fared better with treatment in terms of both
Fig. 3 Coronal MR images in a patient with 
macroadenoma (a) at baseline (volume 
22 702 mm
3), (b) after 24 weeks (volume 
15 285 mm
3) and (c) after 48 weeks (volume 
11 746 mm
3) of treatment with octreotide LAR.
Total 
N = 68
Microadenomas 
N = 8
Macroadenomas
N = 60
Week 24
N 68 8 60
Mean −29 −55 −26
95% Conﬁdence interval [−35, −24] [−70, −40] [−32, −21]
Median −28 −48 −24
SD 23·2 26·4 20·8
Minimum, Maximum −18, −100 −24, −100 −18, −78
Week 48
N 68 8 60
Mean −39 −70 −35
95% Conﬁdence interval [−45, −32] [−87, −53] [−41, −29]
Median −37 −70 −34
SD 26·4 24·5 23·9
Minimum, Maximum −15, −100 −29, −100 −15, −94
Table 5. Changes in tumour volume (expressed 
as negative percentages from baseline)866 M. Mercado et al.
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biochemical response rate and tumour volume reduction.
14,15,23,24 In
contrast to these other studies, however, we did not ﬁnd an improve-
ment in biochemical response with longer duration of treatment.
In responsive patients the effects were detectable within 12 weeks
of starting therapy and were maintained throughout the study.
Amelioration of the biochemical abnormalities was accompanied by
a consistent reduction in the incidence and severity of the symptoms
of the disease including headache, fatigue, perspiration, paresthesia,
osteoarthralgia and carpal tunnel syndrome, which also persisted
throughout the whole study period.
In addition to suppressing the elevated GH and IGF-1 levels and
controlling the signs and symptoms of the disease, octreotide LAR
treatment led to a clear regression of tumour volumes (i.e. > 20%
reduction from initial volume) in all the patients with micro-
adenoma and in approximately 70% of those with macroadenoma.
None of the patients showed an increase in tumour volume (i.e. out-
side the ± 20% measurement error). Even macroadenomas that did
not exceed 20% shrinking still showed a steady reduction in size at
48 weeks. The microadenomas shrank rapidly, with the reduction in
tumour volume being detectable after 24 weeks of therapy in all
patients and the regression increased progressively over time to an
average of 70% volume reduction after 48 weeks. Thus, continuing
therapy with octreotide LAR may be appropriate in patients
with macroadenoma even if the initial responses are small. Studies
with much longer-term follow-up imaging (e.g. at least 2 years
of octreotide LAR therapy) would be required to demonstrate
the ﬁnal time beyond which no further tumour shrinkage could
be expected.
This is the largest study to date to use centralized volume meas-
urement of electronic image data in acromegaly. The volume reduc-
tions found in the present study are consistent with the only previous
study that systematically measured changes in tumour volume in 27
previously untreated GH-secreting tumours during octreotide
therapy,
14 despite differences in the measurement methods (summed area
rather than diameter). While an estimate of volume can be obtained
from lesion diameter measurements, these may not adequately
account for irregularly shaped tumours that are frequent among
macroadenomas, particularly large ones.
17,26,27 Thus, very large macro-
adenomas (in the present study, 25% had a baseline volume of
> 5000 mm
3) are more difﬁcult to measure than smaller lesions, even
Fig. 4 Percentages in tumour volume reduction in micro- and 
macroadenomas throughout the study.
Table 6. Incidence and severity of symptoms at baseline, week 24 and 
week 48
Symptom severity
Baseline 
N = 68 
n (%)
Week 24 
N = 68* 
n (%)
Week 48 
N = 68 
n (%)
Headache
Absent 24 (35·3) 51 (76·1) 53 (77·9)
Mild 21 (30·9) 11 (16·4) 10 (14·7)
Moderate 15 (22·1) 5 (7·5) 4 (5·9)
Severe, not incapacitating 7 (10·3) 0 0
Severe, incapacitating 1 (1·5) 0 1 (1·5)
Fatigue
Absent 25 (36·8) 46 (68·7) 52 (76·5)
Mild 23 (33·8) 16 (23·9) 12 (17·6)
Moderate 13 (19·1) 5 (7·5) 3 (4·4)
Severe, not incapacitating 7 (10·3) 0 0
Severe, incapacitating 0 0 1 (1·5)
Perspiration
Absent 20 (29·4) 50 (74·6) 51 (75·0)
Mild 22 (32·4) 12 (17·9) 9 (13·2)
Moderate 18 (26·5) 3 (4·5) 7 (10·3)
Severe, not incapacitating 6 (8·8) 2 (3·0) 1 (1·5)
Severe, incapacitating 2 (2·9) 0 0
Osteoarthralgia
Absent 17 (25·0) 35 (52·2) 38 (55·9)
Mild 18 (26·5) 22 (32·8) 19 (27·9)
Moderate 22 (32·4) 7 (10·4) 6 (8·8)
Severe, not incapacitating 9 (13·2) 3 (4·5) 5 (7·4)
Severe, incapacitating 2 (2·9) 0 0
Carpal tunnel syndrome
Absent 47 (69·1) 62 (92·5) 66 (97·1)
Mild 13 (19·1) 3 (4·5) 0
Moderate 4 (5·9) 1 (1·5) 2 (2·9)
Severe, not incapacitating 2 (2·9) 1 (1·5) 0
Severe, incapacitating 2 (2·9) 0 0
Paresthesia
Absent 33 (48·5) 61 (91·0) 60 (88·2)
Mild 19 (27·9) 5 (7·5) 7 (10·3)
Moderate 12 (17·6) 1 (1·5) 1 (1·5)
Severe, not incapacitating 3 (4·4) 0 0
Severe, incapacitating 1 (1·5) 0 0
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digitally. Our results strongly suggest that the larger the tumour the
more slowly it shrinks. Of interest, tumour shrinkage was apparent
even in a signiﬁcant proportion of patients with a relatively poor bio-
chemical response rate. This discrepancy between somatostatin
analogue-induced tumour shrinkage and the ability of the compound
to inhibit GH synthesis and secretion has been observed before in
individual cases and appears to be due to the expression of a speciﬁc set
of somatostatin receptor subtypes, particularly the sst3 subtype (as
opposed to the usual expression in these tumours of subtypes 2 and 5).
28,29
Thus, the results of this investigation conﬁrm those published
previously and demonstrate that octreotide LAR fulﬁls all the
requirements for the primary treatment of acromegaly because it can
reverse tumour growth, produce a sustained suppression of the elevated
levels of GH and IGF-1 and control the symptoms of the disease.
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